Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A real world evidence study of COPAXONE (glatiramer acetate or GA) by mothers with multiple sclerosis (MS) who are breastfeeding

Next Previous
X
Search
Trial Profile

A real world evidence study of COPAXONE (glatiramer acetate or GA) by mothers with multiple sclerosis (MS) who are breastfeeding

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glatiramer acetate (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms COBRA

    • Most Recent Events

    • 10 Feb 2022 According to a Teva Pharmaceuticals Europe media release, COPAXONE 20mg/mL and 40mg/mL, indicated for the treatment of relapsing forms of multiple sclerosis (RMS) in Europe, has been updated. The product is now approved by EU health authorities for use in breastfeeding. The label update follows the review of clinical and non-clinical evidence, including latest data from the COBRA real world evidence study.
    • 15 Oct 2021 Results of subgroup analysis assessing offspring outcomes among breastfeeding mothers on glatiramer acetate treatment for relapsing multiple sclerosis, presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 13 Oct 2021 Acording to a Teva Pharmaceuticals Europe media release, subgroup analyses results presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top